Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Scribed by Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, Oleg N; Bair, Angel H; Rosbrook, Brad; Chen, Connie; Kim, Sinil; Vogelzang, Nicholas J

• Book ID: 121333575
• Publisher: The Lancet
• Year: 2013
• Tongue: English
• Weight: 317 KB
• Volume: 14
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/S1470-2045(13)70465-0